Alpa Laboratories Ltd

₹ 99.1 -5.23%

30 May - close price

About

Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals^[1]

Key Points

Business Overview:^[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use

Website BSE NSE

Market Cap ₹ 209 Cr.
Current Price ₹ 99.1
High / Low ₹ 145 / 69.9
Stock P/E 10.6
Book Value ₹ 86.4
Dividend Yield 0.00 %
ROCE 15.0 %
ROE 11.4 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 1.15 times its book value
Company has delivered good profit growth of 29.6% CAGR over last 5 years

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 5.51% over past five years.
Company has a low return on equity of 10.7% over last 3 years.
Earnings include an other income of Rs.24.1 Cr.
Company has high debtors of 153 days.
Working capital days have increased from 257 days to 464 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	25.50	22.42	13.54	27.31	29.16	25.43	32.39	27.31	23.61	21.44	24.94	26.15	39.11
	26.86	21.00	19.28	24.68	19.90	26.58	29.07	24.85	20.10	20.90	21.67	25.41	39.47
Operating Profit	-1.36	1.42	-5.74	2.63	9.26	-1.15	3.32	2.46	3.51	0.54	3.27	0.74	-0.36
OPM %	-5.33%	6.33%	-42.39%	9.63%	31.76%	-4.52%	10.25%	9.01%	14.87%	2.52%	13.11%	2.83%	-0.92%
	3.72	1.61	6.38	2.69	-0.76	4.47	2.95	3.55	3.97	5.18	6.91	8.80	3.24
Interest	0.07	0.03	0.08	0.07	0.04	0.02	0.04	0.03	0.30	0.05	0.06	0.10	0.05
Depreciation	0.50	0.34	0.36	0.10	0.53	0.28	0.49	0.66	0.52	0.54	0.53	0.55	0.58
Profit before tax	1.79	2.66	0.20	5.15	7.93	3.02	5.74	5.32	6.66	5.13	9.59	8.89	2.25
Tax %	304.47%	0.00%	0.00%	0.00%	41.74%	0.00%	0.00%	14.85%	46.70%	0.00%	20.44%	0.00%	186.67%
	-3.66	2.66	0.20	5.14	4.62	3.03	5.74	4.53	3.55	5.12	7.63	8.89	-1.95
EPS in Rs	-1.74	1.26	0.10	2.44	2.20	1.44	2.73	2.15	1.69	2.43	3.63	4.23	-0.93
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	56	57	53	63	62	77	85	97	112	93	109	112
	51	54	47	56	57	76	79	90	101	85	100	107
Operating Profit	6	3	7	7	4	1	6	8	11	8	9	4
OPM %	10%	6%	13%	11%	7%	2%	7%	8%	10%	9%	8%	4%
	1	2	6	4	5	5	0	4	11	9	14	24
Interest	2	2	1	2	1	1	0	0	0	0	0	0
Depreciation	9	6	1	1	1	1	1	1	2	1	2	2
Profit before tax	-5	-3	11	9	7	5	5	11	20	16	21	26
Tax %	4%	-48%	27%	34%	27%	36%	20%	33%	28%	21%	19%	24%
	-5	-1	8	6	5	3	4	7	14	13	17	20
EPS in Rs	-2.45	-0.67	3.68	2.85	2.27	1.40	1.94	3.45	6.72	6.00	7.98	9.35
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	7%
5 Years:	6%
3 Years:	0%
TTM:	3%

Compounded Profit Growth
10 Years:	55%
5 Years:	30%
3 Years:	36%
TTM:	14%

Stock Price CAGR
10 Years:	24%
5 Years:	40%
3 Years:	15%
1 Year:	22%

Return on Equity
10 Years:	7%
5 Years:	9%
3 Years:	11%
Last Year:	11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	21	21	21	21	21	21	21	21	21	21	21	21
Reserves	67	66	73	77	82	85	89	96	111	124	141	161
	23	29	24	11	6	2	0	0	6	3	5	0
	15	13	27	20	17	21	21	33	28	30	25	51
Total Liabilities	127	128	145	129	127	129	131	150	165	178	192	233
	73	5	5	5	6	6	6	7	9	7	11	21
CWIP	0	0	0	0	0	0	1	2	0	0	0	0
Investments	0	10	22	23	41	59	68	62	86	90	109	129
	54	113	118	100	79	64	56	80	70	81	72	83
Total Assets	127	128	145	129	127	129	131	150	165	178	192	233

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	8	-2	-25	-8	-7	-1	18	-1	2	10	4
	-2	37	-7	1	-16	-15	-11	6	-16	1	-12
	4	7	-6	-2	4	-5	-1	-0	5	-3	2
Net Cash Flow	10	42	-37	-9	-19	-20	5	4	-8	8	-6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	130	156	234	169	151	141	105	133	124	186	138	153
Inventory Days	148	76	196	131	140	105	90	102	81	84	73	92
Days Payable	121	91	244	140	130	99	98	152	78	100	63	97
Cash Conversion Cycle	157	141	187	160	161	148	97	83	127	170	149	148
Working Capital Days	169	178	390	256	234	194	121	137	136	157	150	464
ROCE %	-3%	0%	10%	11%	7%	4%	7%	7%	9%	11%	14%	15%

Shareholding Pattern

Numbers in percentages

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%
	0.21%	0.14%	0.00%	0.00%	0.00%	0.11%	0.95%	0.50%	0.36%	0.74%	0.35%	0.40%
	0.00%	0.00%	0.00%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	42.50%	42.56%	42.70%	42.70%	42.70%	42.59%	41.74%	42.21%	42.35%	41.97%	42.34%	42.30%
No. of Shareholders	18,796	18,840	19,094	19,137	18,745	18,565	18,682	18,690	18,116	18,885	19,206	18,872

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	54.61%	54.61%	56.66%	56.66%	56.66%	57.29%	57.29%	57.29%	57.29%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%	0.00%	0.50%	0.40%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%
	45.39%	45.39%	43.34%	43.34%	43.34%	42.15%	42.70%	42.21%	42.30%
No. of Shareholders	12,229	12,684	12,465	12,204	13,240	18,775	19,137	18,690	18,872

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Alpa Laboratories Ltd

Alpa Laboratories Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings